Symptoms of Huntington's disease appear late in life. Research reveals how DNA repeats grow toxic over time, explaining the ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Advances in genetic testing, enable the identification of genetic causes even before symptoms appear, allowing for timely ...

LEXINGTON, Mass. - uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, ...

EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company"). Atalanta, a biotechnology company based in ...

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

A novel in vivo screening strategy identifies new modifiers of somatic CAG repeat expansion that contribute to age of onset in Huntington’s disease.

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.